NCT01867294
Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab
See it on ClinicalTrials.gov ↗17 people
23.5%
76.5%
4 womenmiddle line = equal numbers13 men
- Phase
- PHASE2
- Paid for by
- Academic and Community Cancer Research United
- Finished
- 2014-06-13
- Health conditions
- Advanced Malignant Neoplasm, Dermatologic Complication
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- median 62.6 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No cancer
Women with current or past cancer were turned away.
“Any other disorder that may predispose to hyperkalemia in the opinion of the treating oncologist”
Study titles and rules are shown in their original English.